Basit öğe kaydını göster

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

dc.contributor.authorDvorkin, Mikhail
dc.contributor.authorHochmair, Maximilian J.
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorJi, Jun Ho
dc.contributor.authorGarassino, Marina Chiara
dc.contributor.authorVoitko, Oleksandr
dc.contributor.authorPoltoratskiy, Artem
dc.contributor.authorPonce, Santiago
dc.contributor.authorVerderame, Francesco
dc.contributor.authorHavel, Libor
dc.contributor.authorBondarenko, Igor
dc.contributor.authorKazarnowicz, Andrzej
dc.contributor.authorLosonczy, Gyorgy
dc.contributor.authorConev, Nikolay V.
dc.contributor.authorArmstrong, Jon
dc.contributor.authorByrne, Natalie
dc.contributor.authorThiyagarajah, Piruntha
dc.contributor.authorJiang, Haiyi
dc.contributor.authorPaz-Ares, Luis
dc.contributor.authorTrukhin, Dmytro
dc.contributor.authorHotta, Katsuyuki
dc.contributor.authorStatsenko, Galina
dc.contributor.authorReinmuth, Niels
dc.contributor.authorChen, Yuanbin
dc.contributor.authorGoldman, Jonathan W.
dc.date.accessioned2021-03-02T15:46:28Z
dc.date.available2021-03-02T15:46:28Z
dc.date.issued2021
dc.identifier.citationGoldman J. W. , Dvorkin M., Chen Y., Reinmuth N., Hotta K., Trukhin D., Statsenko G., Hochmair M. J. , ÖZGÜROĞLU M., Ji J. H. , et al., "Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial", LANCET ONCOLOGY, cilt.22, sa.1, ss.51-65, 2021
dc.identifier.issn1470-2045
dc.identifier.othervv_1032021
dc.identifier.otherav_4188a4b9-45bd-4930-a358-be601b1f4ed1
dc.identifier.urihttp://hdl.handle.net/20.500.12627/1720
dc.identifier.urihttps://doi.org/10.1016/s1470-2045(20)30539-8
dc.description.abstractBackground First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum-etoposide) showed a significant improvement in overall survival versus platinum-etoposide alone in patients with extensive-stage smallcell lung cancer (ES-SCLC) in the CASPIAN study. Here we report updated results, including the primary analysis for overall survival with durvalumab plus tremelimumab plus platinum-etoposide versus platinum-etoposide alone.
dc.language.isoeng
dc.subjectOncology
dc.subjectHealth Sciences
dc.subjectONKOLOJİ
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectOnkoloji
dc.titleDurvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
dc.typeMakale
dc.relation.journalLANCET ONCOLOGY
dc.contributor.departmentDavid Geffen School of Medicine at UCLA , ,
dc.identifier.volume22
dc.identifier.issue1
dc.identifier.startpage51
dc.identifier.endpage65
dc.contributor.firstauthorID2522056


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster